广发港股创新药ETF联接(QDII)A(019670)财务指标
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 本期已实现收益 |
-22,675,450.83 |
13,346,631.41 |
3,504,011.95 |
454,201.24 |
| 本期利润 |
-129,226,412.87 |
-47,182,576.95 |
48,039,883.58 |
-68,899.14 |
| 加权平均基金份额本期利润 |
-0.16 |
-0.14 |
0.41 |
0.00 |
| 本期加权平均净值利润率(%) |
-12.73 |
-10.12 |
40.73 |
-0.26 |
| 本期基金份额净值增长率(%) |
-10.69 |
59.53 |
51.46 |
-11.51 |
| 期末可供分配利润 |
-15,957,726.97 |
5,650,424.31 |
-2,964,410.95 |
-11,810,392.50 |
| 期末可供分配基金份额利润 |
-0.02 |
0.01 |
-0.01 |
-0.21 |
| 期末基金资产净值 |
885,275,748.84 |
902,992,071.54 |
246,529,056.61 |
44,821,890.56 |
| 期末基金份额净值 |
1.13 |
1.26 |
1.20 |
0.79 |
| 基金份额累计净值增长率(%) |
12.77 |
26.27 |
19.88 |
-20.85 |
微信公众号
证券之星APP
基本资料
